The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions.

##STR00001##

The present application relates to psilocin derivatives of Formula (1), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.

##STR00001##

The present disclosure includes azetidinyl tryptamines and methods of treating psychiatric disorders with such compounds. Also provided are pharmaceutical compositions that include azetidinyl tryptamines.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention relates to compositions and methods for treating ophthalmic conditions.

The present disclosure relates to display technologies, and particularly discloses an organic electroluminescent device. This organic electroluminescent device includes a light-emitting layer, the light-emitting includes an exciplex composed of a donor molecule and an acceptor molecule, and a wide band gap material for increasing the inter-molecular spacing between the donor molecule and the acceptor molecule. According to the device of the present disclosure, the degree of orbital overlap of HOMO and LUMO of the formed exciplex and the singlet-triplet energy level difference can be reduced, the reverse intersystem crossing rate (k.sub.RISC) of the exciplex host can be increased, the Föster energy transferred to the guest molecule can be enhanced, and the efficiency and the lifetime of the device can be improved.

Disclosed are novel halogenated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced using a biosynthetic system which comprises cells comprising a psilocybin biosynthetic enzyme complement.

The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disorders, among others CNS disorders.

##STR00001##

The present disclosure relates to the field of organic electroluminescence materials and particularly relates to a compound and an organic light emitting display device. The compound has a structure represented by Formula (I): ##STR00001##
and, m, n, p, q, r, s, u, and v are each independently selected from 0 or 1, at least one of r and s is 1, at least one of u and v is 1, L.sub.1, L.sub.2, L.sub.3, and L.sub.4 are each independently selected from substituted or unsubstituted C6-C40 aryl, or substituted or unsubstituted C3-C40 heterocyclyl, and A.sub.1, A.sub.2, A.sub.3, and A.sub.4 each are independently selected from an electron acceptor unit.

The invention relates to a co-crystal or salt comprising psilocybin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.